492 related articles for article (PubMed ID: 32679055)
1. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
Pizzorno A; Padey B; Dubois J; Julien T; Traversier A; Dulière V; Brun P; Lina B; Rosa-Calatrava M; Terrier O
Antiviral Res; 2020 Sep; 181():104878. PubMed ID: 32679055
[TBL] [Abstract][Full Text] [Related]
2. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL
Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767
[TBL] [Abstract][Full Text] [Related]
3. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
4. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Wang M; Cao R; Zhang L; Yang X; Liu J; Xu M; Shi Z; Hu Z; Zhong W; Xiao G
Cell Res; 2020 Mar; 30(3):269-271. PubMed ID: 32020029
[No Abstract] [Full Text] [Related]
5. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
7. Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Dong L; Hu S; Gao J
Drug Discov Ther; 2020; 14(1):58-60. PubMed ID: 32147628
[TBL] [Abstract][Full Text] [Related]
8. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
9. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
Jorgensen SCJ; Kebriaei R; Dresser LD
Pharmacotherapy; 2020 Jul; 40(7):659-671. PubMed ID: 32446287
[TBL] [Abstract][Full Text] [Related]
10. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
11. A Review of Remdesivir for COVID-19: Data to Date.
Mehta M; Shyh GI
Cardiol Rev; 2020; 28(6):332-334. PubMed ID: 32773440
[TBL] [Abstract][Full Text] [Related]
12. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
13. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
[TBL] [Abstract][Full Text] [Related]
14. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):585-586. PubMed ID: 32439198
[TBL] [Abstract][Full Text] [Related]
15. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
16. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
Riva L; Yuan S; Yin X; Martin-Sancho L; Matsunaga N; Pache L; Burgstaller-Muehlbacher S; De Jesus PD; Teriete P; Hull MV; Chang MW; Chan JF; Cao J; Poon VK; Herbert KM; Cheng K; Nguyen TH; Rubanov A; Pu Y; Nguyen C; Choi A; Rathnasinghe R; Schotsaert M; Miorin L; Dejosez M; Zwaka TP; Sit KY; Martinez-Sobrido L; Liu WC; White KM; Chapman ME; Lendy EK; Glynne RJ; Albrecht R; Ruppin E; Mesecar AD; Johnson JR; Benner C; Sun R; Schultz PG; Su AI; García-Sastre A; Chatterjee AK; Yuen KY; Chanda SK
Nature; 2020 Oct; 586(7827):113-119. PubMed ID: 32707573
[TBL] [Abstract][Full Text] [Related]
17. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
Yuan S; Chan CC; Chik KK; Tsang JO; Liang R; Cao J; Tang K; Cai JP; Ye ZW; Yin F; To KK; Chu H; Jin DY; Hung IF; Yuen KY; Chan JF
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532085
[TBL] [Abstract][Full Text] [Related]
18. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Carradori S
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
[No Abstract] [Full Text] [Related]
19. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
[TBL] [Abstract][Full Text] [Related]
20. GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.
Hattori SI; Higshi-Kuwata N; Raghavaiah J; Das D; Bulut H; Davis DA; Takamatsu Y; Matsuda K; Takamune N; Kishimoto N; Okamura T; Misumi S; Yarchoan R; Maeda K; Ghosh AK; Mitsuya H
mBio; 2020 Aug; 11(4):. PubMed ID: 32820005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
